SEC Comment Letter 0000000000-24-004447 to Virpax Pharmaceuticals, Inc. (VRPX) (CIK 0001708331)
Virpax Pharmaceuticals, Inc. (VRPX) (CIK 0001708331)
Date: April 23, 2024 · CIK: 0001708331 · Accession: 0000000000-24-004447
AI Filing Summary & Sentiment
File numbers found in text: 333-278796
Letter
United States securities and exchange commission logo April 23, 2024 Gerald Bruce Chief Executive Officer Virpax Pharmaceuticals, Inc. 1055 Westlakes Drive, Suite 300 Berwyn, PA 19312 Re:Virpax Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed April 18, 2024 File No. 333-278796 Dear Gerald Bruce: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Melissa Palat Murawsky, Esq.
Show Raw Text
United States securities and exchange commission logo
April 23, 2024
Gerald Bruce
Chief Executive Officer
Virpax Pharmaceuticals, Inc.
1055 Westlakes Drive, Suite 300
Berwyn, PA 19312
Re:Virpax Pharmaceuticals, Inc.
Registration Statement on Form S-1
Filed April 18, 2024
File No. 333-278796
Dear Gerald Bruce:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Melissa Palat Murawsky, Esq.